CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 679,000 shares, a growth of 86.2% from the September 15th total of 364,600 shares. Based on an average trading volume of 4,670,000 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research note on Tuesday, September 10th.

CNS Pharmaceuticals Stock Performance

Shares of CNSP opened at $0.12 on Monday. The firm has a market cap of $170,706.90, a PE ratio of 0.00 and a beta of 2.57. CNS Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $137.50. The firm’s 50 day moving average price is $0.15 and its 200 day moving average price is $4.63.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

Institutional Trading of CNS Pharmaceuticals

An institutional investor recently raised its position in CNS Pharmaceuticals stock. Virtu Financial LLC lifted its stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 94,246 shares of the company’s stock after acquiring an additional 81,094 shares during the period. Virtu Financial LLC owned 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent reporting period. 14.02% of the stock is currently owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.